MedPath

Treatment of sialorrhea by combined use of muscarinic M1 and M3 receptor selective antagonists

Phase 1
Conditions
sialorrhea
Registration Number
JPRN-UMIN000031765
Lead Sponsor
Tokyo Women's medical university
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
6
Inclusion Criteria

Not provided

Exclusion Criteria

retention sialorrhea

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sialorrhea Clinical Scale for PD during 12 weeks
Secondary Outcome Measures
NameTimeMethod
salivary flow rate (rest and stimulated) during 12 weeks
© Copyright 2025. All Rights Reserved by MedPath